Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
Posted inClinical Updates Gastroenterology Internal Medicine news Specialties

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and diabetic populations.
Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial
Posted inCardiology Clinical Updates news Specialties

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential for mortality risk reduction.
Evaluating the Impact of Vitamin D3, Omega-3 Fatty Acids, and Home Exercise on Vertebral Fracture Prevention in Older Adults: Insights from the DO-HEALTH Trial
Posted inClinical Updates Family Medicine & Nutrition news Orthopedics Specialties

Evaluating the Impact of Vitamin D3, Omega-3 Fatty Acids, and Home Exercise on Vertebral Fracture Prevention in Older Adults: Insights from the DO-HEALTH Trial

The DO-HEALTH trial found that vitamin D3 and omega-3 supplementation did not reduce vertebral fracture rates in healthy seniors, while a simple home exercise program lowered fracture incidence in women and slowed fracture progression overall, highlighting exercise’s potential role in vertebral fracture prevention.
Posted inClinical Updates news Oncology Specialties

Methylcobalamin Significantly Reduces Severe Hand-Foot Syndrome in HER2 Negative Early Breast Cancer Patients Receiving Capecitabine: Results from a Phase 3 Randomised Trial

Oral methylcobalamin notably decreased the incidence of grade ≥2 hand-foot syndrome in patients with HER2 negative early breast cancer undergoing adjuvant capecitabine treatment, without added safety concerns, improving treatment adherence potential.